Properties (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
gptkb:secukinumab
|
| gptkbp:administrativeDivision |
once a month after initial loading doses
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Cosentyx
|
| gptkbp:chemicalFormula |
C6420H9924N1716O1980S44
|
| gptkbp:clinicalTrials |
Phase III
FUTURE 1 FUTURE 2 MEASURE 1 MEASURE 2 active ankylosing spondylitis active psoriatic arthritis moderate to severe plaque psoriasis non-radiographic axial spondyloarthritis chronic plaque psoriasis MAXIMIZE |
| gptkbp:contraindication |
active infections
hypersensitivity_to_secukinumab |
| gptkbp:dosageForm |
solution for injection
|
| gptkbp:endOfLife |
about 27 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
secukinumab
|
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2015
|
| gptkbp:mandates |
treatment of non-radiographic axial spondyloarthritis in adults
treatment of moderate to severe plaque psoriasis in adults treatment of active ankylosing spondylitis in adults treatment of active psoriatic arthritis in adults |
| gptkbp:manufacturer |
Novartis
|
| gptkbp:marketedAs |
over 80 countries
|
| gptkbp:numberOfStudents |
primarily through the reticuloendothelial system
|
| gptkbp:patentExpiration |
2026
|
| gptkbp:safetyFeatures |
monitor for signs of infection
TB screening recommended before initiation monitor for hypersensitivity reactions monitor for inflammatory bowel disease |
| gptkbp:sideEffect |
headache
nausea injection site reactions upper respiratory infections |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
IL-17A
|
| gptkbp:triggerType |
IL-17A inhibition
|
| gptkbp:usedFor |
treatment of psoriasis
treatment of ankylosing spondylitis treatment of psoriatic arthritis |
| gptkbp:weight |
146 kDa
|